指南与共识重症综合管理与镇静镇痛中毒与环境急症复苏、休克与脓毒症

血液吸附:第30届急性疾病质量倡议工作组共识报告

Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup.
指南 / 共识 · Nephrol Dial Transplant · 2024-01-01
一句话结论血液吸附短期生物相容性和安全性可接受,但除内毒素吸附外多数指征证据有限,仍属实验性干预,需大型随机对照试验。

血液吸附技术已发展近五十年,近期膜与吸附剂技术进步使其生物相容性改善,应用扩展到中毒、药物过量、炎症与脓毒症、急慢性肝肾功能衰竭。第30届急性疾病质量倡议(ADQI)共识会议汇总证据:血液吸附具有临床可接受的短期生物相容性和安全性、技术可行性,并在体外实验中证实可清除特定目标分子;内毒素吸附的较大规模研究识别出可能的目标表型,为大型随机对照试验提供依据;多种内源性和外源性中毒中目标分子清除已在体内证实。但部分研究提示可能有害或未能带来获益,现代血液吸附仍属新颖且实验性的干预,数据有限,研究议程庞大。

要点

  • 血液吸附具有临床可接受的短期生物相容性和安全性、技术可行性,体外实验证实可清除特定目标分子。
  • 内毒素吸附的较大规模研究已识别出可能的目标表型,为大型随机对照试验提供依据。
  • 多种内源性和外源性中毒中,目标分子清除已在体内得到证实。
  • 部分研究提示可能有害或未能带来获益,现代血液吸附仍属新颖且实验性的干预,数据有限。
  • 试点研究显示对生理学指标可能有获益,但需更大规模随机对照试验验证。

适用人群与场景

  • 中毒、药物过量患者
  • 炎症状态与脓毒症患者
  • 急性或慢性肝衰竭、肾衰竭患者

研究设计与关键结果

  • 血液吸附具有临床可接受的短期生物相容性和安全性、技术可行性,并在实验层面证实可清除特定目标分子。
  • 试点研究显示对生理学指标可能有获益;内毒素吸附的较大规模研究识别出可能的目标表型,为大型随机对照试验提供依据。
  • 多种内源性和外源性中毒中,目标分子清除已在体内得到证实。
  • 部分研究提示可能有害或未能带来获益。

证据类型、等级与局限

  • 证据类型:第30届急性疾病质量倡议(ADQI)共识会议报告,基于体外、实验和临床观察汇总。
  • 现代血液吸附仍属新颖且实验性的干预,数据有限,研究议程庞大。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 血液吸附短期生物相容性和安全性可接受、技术可行,但多数指征证据有限,仍属实验性干预,不宜作为常规推荐。
  • 内毒素吸附的较大规模研究已识别可能的目标表型,为设计大型随机对照试验提供方向。
  • 部分研究提示可能有害或未能带来获益,临床应用需权衡。

指南或共识出处

  • 第30届急性疾病质量倡议(Acute Disease Quality Initiative, ADQI)工作组共识报告,发表于 Nephrol Dial Transplant

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Adsorption-based extracorporeal therapies have been subject to technical developments and clinical application for close to five decades. More recently, new technological developments in membrane and sorbent manipulation have made it possible to deliver more biocompatible extracorporeal adsorption therapies to patients with a variety of conditions. There are several key rationales based on physicochemical principles and clinical considerations that justify the application and investigation of such therapies as evidenced by multiple ex vivo, experimental and clinical observations. Accordingly, unspecific adsorptive extracorporeal therapies have now been applied to the treatment of a wide array of conditions from poisoning to drug overdoses, to inflammatory states and sepsis, and acute or chronic liver and kidney failure. In response to the rapidly expanding knowledge base and increased clinical evidence, we convened an Acute Disease Quality Initiative consensus conference dedicated to such treatment. The data show that hemoadsorption has clinically acceptable short-term biocompatibility and safety, technical feasibility and experimental demonstration of specified target molecule removal. Pilot studies demonstrate potentially beneficial effects on physiology and larger studies of endotoxin-based hemoadsorption have identified possible target phenotypes for larger randomized controlled trials. Moreover, in a variety of endogenous and exogenous intoxications, removal of target molecules has been confirmed in vivo. However, some studies have raised concerns about harm, or failed to deliver benefits. Thus, despite many achievements, modern hemoadsorption remains a novel and experimental intervention with limited data, and a large research agenda.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

参考来源

  1. Bellomo R, Ankawi G, Bagshaw SM, et al. Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup. Nephrol Dial Transplant. 2024. PMID: 38621759. doi:10.1093/ndt/gfae089

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。